Hypercalcaemic hyperparathyroidism has been diagnosed more commonly in recent years. This reflects an increasing awareness of and a growing interest in the disease. In the search for possible aetiologic mechanisms behind the development of parathyroid adenomata, certain environmental factors have been suggested. This study indicates that a significantly (p less than 0.01) greater number of patients who had parathyroid adenomata had previously undergone radiation therapy involving the neck region compared with normocalcaemic control subjects. The observed and controlled cases originate from a medical screening programme done as part of a health check-up including almost 16 000 persons in the Stockholm area. It is recommended that special attention to a past history of possible neck irradiation be paid in subjects suspected of suffering from hyperparathyroidism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7326/0003-4819-89-2-216 | DOI Listing |
Background: Intrahepatic cholangiocarcinoma (ICC) presents a significant clinical challenge due to its high fatality rate and limited surgical candidacy. With only 30-40% of patients eligible for surgery upon diagnosis, alternative therapies are imperative. This study assesses the efficacy of Yttrium-90 (Y-90) radioembolization for unresectable ICC patients in a non-university tertiary care center (NUTCC).
View Article and Find Full Text PDFHeliyon
January 2025
Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, 56212, Republic of Korea.
The suppression of tyrosinase (TYR), a key enzyme in melanogenesis, has been suggested as an effective strategy for preventing melanin accumulation. We previously discovered the novel chrysin derivative hydroxyethyl chrysin (HE-chrysin) through an irradiation technique, which exerted higher anti-inflammatory and anti-cancer activities than original chrysin. In the present study, we explored whether HE-chrysin has antioxidant and anti-melanogenic capacity using B16F10 murine melanoma cells and molecular docking.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or metastatic disease. With the emergence of immune checkpoint inhibitors and targeted therapies for specific genomic aberrations in the treatment of over a dozen other cancers, recent studies have sought to identify therapies other than chemotherapy in treating this uncommon cancer. Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.
View Article and Find Full Text PDFJCEM Case Rep
February 2025
First Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
SARS-CoV-2 infection could trigger autoimmune disease. We report a case of concomitant exacerbation of Graves orbitopathy (GO) and myasthenia gravis (MG) after SARS-CoV-2 infection. A 43-year-old woman had diplopia, proptosis, and swollen eyelids.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Primary squamous cell carcinoma of the thyroid (PSCCT) has recently been reclassified as a morphologic pattern of anaplastic thyroid carcinoma (ATC). Consequently, PSCCT and squamous cell carcinoma with papillary thyroid carcinoma (SCC-PTC) were categorized as ATC. However, in terms of clinical characteristics and overall prognosis, whether PSCCT is similar to SCC-PTC has yet to be sufficiently investigated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!